WellSpan Health – Innovations & Advancements in Cancer Treatment
A York County business owner is sharing his story of hope after completing an innovative cancer treatment at WellSpan York Hospital. John Grim has been battling prostate cancer for nearly seven years, and after multiple treatments failed, doctors offered him a chance to try something knew. Janel Knight told us his story this morning.
John Grim's doctor and Medical Director of Radiation Oncology at WellSpan Health, Dr. Navesh Sharma, spoke with Amy about Pluvicto, new cancer treatments being offered at WellSpan Health, Proton Therapy, and more.
As part of today's special Good Day PA, abc27 and WellSpan Health hosted a live webchat. Dr. Jaganmohan Poli, Radiation Oncologist at WellSpan Health, answered viewer submitted questions about radiation oncology and radiation therapy.
Amy spoke with Dr. Scott Tiedbohl, Thoracic Surgeon at WellSpan Health, to learn more about lung cancer screening, advancements in technology and treatments, and how these benefit patients and the community.
WellSpan Cancer Institute is proud of it's efforts to truly listen to patients, allowing experts to customize treatment options while offering compassionate care. Amy spoke with Dr. Nik Korgaonkar to learn more.
Dr. Poli joined Janel again later in the show to answer more viewer questions.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 hours ago
- Yahoo
WellSpan Health adds local practices to care network
(WHTM) — WellSpan Health announced they are expanding its care network this summer. According to WellSpan Health, the following primary and specialty care practices will soon join the network in WellSpan's north region: Numerous Family Practice Center PC (FPC) locations, including Bloomsburg, Duboistown, Elysburg, Herndon, Hughesville, Lewisburg, Middleburg, Mifflinburg, Montoursville, Mt. Pleasant Mills, Muncy, Selinsgrove, Shamokin Dam, Sunbury, Watsontown, and Williamsport The Eye Center of Central PA and The Surgery Center of Central PA Ideal Pediatric & Adolescent Care PC David C. Holman, DPM a local podiatrist The following primary and specialty care practices are set to join the network in WellSpan's west region: Greencastle Family Practice Waynesboro Family Medical Associates Pediatric Specialists of Franklin County Cumberland Valley Retina Consultants WellSpan says all Dermatology Partners, with locations all across the Commonwealth, will also be joining the network. Close Thanks for signing up! Watch for us in your inbox. Subscribe Now 'WellSpan's commitment to offering access to high-quality care extends beyond our own practices, as we partner with like-minded providers who are equally committed to serving this region,' said Dr. Anthony Aquilina, executive vice president and chief physician executive, WellSpan Health. 'Joining a larger health system like WellSpan continues to provide benefit to the community we serve, and it benefits our team members who now have access to an expanded group of doctors close to home for their family and their own personal care,' said Kendra Aucker, senior vice president of WellSpan's north region and president, WellSpan Evangelical Community Hospital. WellSpan says the new providers will join the network on July 1, 2025. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
18 hours ago
- Yahoo
WellSpan Provider Network expands robust network of care
This expansion will enhance access to high-quality, in-network care for patients with medical coverage provided by WellSpan across the region. York, Pa., June 11, 2025 (GLOBE NEWSWIRE) -- WellSpan Health is pleased to announce the expansion of its WellSpan Provider Network (WPN) this summer with key providers and practices across the region joining the network. This ensures convenient access for patients with medical coverage provided by WellSpan. The following primary and specialty care practices are set to join the network's enhanced tier in WellSpan's north region: Numerous Family Practice Center PC (FPC) locations, including Bloomsburg, Duboistown, Elysburg, Herndon, Hughesville, Lewisburg, Middleburg, Mifflinburg, Montoursville, Mt. Pleasant Mills, Muncy, Selinsgrove, Shamokin Dam, Sunbury, Watsontown and Williamsport The Eye Center of Central PA and The Surgery Center of Central PA Ideal Pediatric & Adolescent Care PC David C. Holman, DPM a local podiatrist The following primary and specialty care practices are set to join the network's enhanced tier in WellSpan's west region: Greencastle Family Practice Waynesboro Family Medical Associates Pediatric Specialists of Franklin County Cumberland Valley Retina Consultants Dermatology Partners, with numerous locations throughout all of central Pennsylvania will also be joining the network. 'WellSpan's commitment to offering access to high-quality care extends beyond our own practices, as we partner with like-minded providers who are equally committed to serving this region," said Dr. Anthony Aquilina, executive vice president and chief physician executive, WellSpan Health. The new providers join the network's enhanced tier effective July 1, 2025. 'Joining a larger health system like WellSpan continues to provide benefit to the community we serve, and it benefits our team members who now have access to an expanded group of doctors close to home for their family and their own personal care,' said Kendra Aucker, senior vice president of WellSpan's north region and president, WellSpan Evangelical Community Hospital. 'At WellSpan we know it takes a collaborative approach to meet all the needs of the communities we serve and this ensures that access is not a factor,' said Niki Hinckle, senior vice president of WellSpan's west region. WellSpan also offers local employers health care coverage options as part of its Well at Work program. The program supports nearly 700 employer groups across the region, providing clinical services, occupational health, wellness and well-being support in addition to other features. To learn more about it, visit Attachment This expansion will enhance access to high-quality, in-network care for patients with medical coverage provided by WellSpan across the region. CONTACT: Maggi Barton WellSpan Health 717-851-3151 Mbarton8@ in to access your portfolio
Yahoo
03-06-2025
- Yahoo
Novartis reports topline outcomes from trial of Pluvicto for prostate cancer
Novartis has reported topline outcomes from the Phase III PSMAddition trial's pre-specified interim analysis, where Pluvicto (lutetium (177Lu) vipivotide tetraxetan), plus standard of care (SoC), has demonstrated a benefit in treating prostate-specific membrane antigen (PSMA)-positive metastatic hormone-sensitive prostate cancer (mHSPC). The open-label trial met its primary endpoint, with the combo showing radiographic progression-free survival (rPFS) benefits with a positive trend in overall survival (OS) in this subject population. The SoC in the PSMAddition trial includes a combo of androgen receptor pathway inhibitor (ARPI) therapy and androgen deprivation therapy (ADT). This is the third positive read-out for this intravenous radioligand therapy (RLT), Pluvicto, in a Phase III trial, after the VISION and PSMAfore trials. According to the company, findings from PSMAddition for mHSPC treatment show potential for treatment in an earlier setting with the RLT. PSMAddition is a prospective, randomised trial that assesses the safety and efficacy of Pluvicto plus SoC versus SoC alone. Subjects in the SoC arm are permitted to cross over to receive the RLT upon radiographic progression, as confirmed by a blinded independent review committee (BIRC). Novartis noted that detailed data from the PSMAddition trial will be presented at a future medical meeting and submitted for regulatory review later this year. The US Food and Drug Administration (FDA) recently approved the RLT for earlier use in mCRPC, based on outcomes from the PSMAfore trial. Novartis Development president and chief medical officer Shreeram Aradhye said: 'The progression from metastatic hormone-sensitive prostate cancer to castration-resistant disease remains a formidable challenge that can profoundly impact the survival of patients. 'Following the recent FDA approval based on the PSMAfore trial in metastatic castration-resistant prostate cancer, these data suggest using it in an earlier disease setting could advance care and address a significant unmet need for hormone-sensitive prostate cancer patients." This March, Novartis reported positive efficacy and safety outcomes from the Phase III clinical programme for OAV101 IT (onasemnogene abeparvovec), an investigational intrathecal therapy intended for spinal muscular atrophy (SMA) in subjects aged two to less than 18 years. "Novartis reports topline outcomes from trial of Pluvicto for prostate cancer " was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
